Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma

Dinnes, Jacqueline; Ruffano, Lavinia Ferrante di; Takwoingi, Yemisi; Nathan, Paul; Matin, Rubeta; Chuchu, Naomi; Chan, Sue Ann; Durack, Alana; Bayliss, Sue; Gulati, Abha; Patel, Lopa; Davenport, Clare; Godfrey, Kathie; Subesinghe, Manil; Traill, Zoë; Deeks, Jonathan J; Williams, Hywel C

doi:10.1002/14651858.cd012806.pub2

Cited by 46 publications

(64 citation statements)

References 403 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Despite this, upstaging and a change in the pre-scan management plan in 16% of patients imply a meaningful impact. The importance of changes in disease management has been affirmed in the recently published Cochrane review on staging imaging in melanoma [ 10 ]. In the present study, MRI of the brain never revealed a metastasis at baseline and its usefulness in this setting therefore appears dubious.…”

Section: Discussionmentioning

confidence: 99%

Staging 18F-FDG PET/CT influences the treatment plan in melanoma patients with satellite or in-transit metastases

et al. 2020

View full text Add to dashboard Cite

Whole-body positron emission tomography/computed tomography (PET/CT) and brain magnetic resonance imaging (MRI) are commonly used to stage patients with palpable lymph node metastases from melanoma, but their role in patients with satellite and/or in-transit metastasis (S&ITM) is unclear. The aim of this study was to establish the diagnostic value of PET/CT and brain MRI in these patients, and to assess their influence on subsequent management decisions. In this prospective study, 25 melanoma patients with a first presentation of S&ITM who had no clinical evidence of palpable nodal or distant metastasis underwent whole-body 18 F-FDG PET/CT and brain MRI after a tentative pre-scan treatment plan had been made. Sensitivity and specificity of imaging were determined by pathological confirmation, clinical outcome and repeat PET/CT and MRI at 6 months. PET/CT led to a modification of the initial treatment plan in four patients (16%). All four were upstaged (AJCC stage eighth edition). PET/CT was false-positive in one patient, who had a Schwannoma in his trapezius muscle. A thyroid carcinoma was an incidental finding in another patient. The sensitivity of PET/CT was 58% and specificity 83%. In 6 months following the baseline PET/CT, further sites of in-transit or systemic disease were identified in 10 patients (40%). Brain MRI did not alter the treatment plan or change the disease stage in any patient. Whole-body PET/CT improved staging in melanoma patients with S&ITM and changed the originally-contemplated treatment plan in 16%. MRI of the brain appeared not to be useful.

show abstract

Section: Discussionmentioning

confidence: 99%

Staging 18F-FDG PET/CT influences the treatment plan in melanoma patients with satellite or in-transit metastases

et al. 2020

View full text Add to dashboard Cite

show abstract

“… Tanshinone I and simvastatin significantly inhibit proliferation and PARP1 expression in melanoma A-375 cells. (A) Western blotting was used to determine the effects of mefloquine ( 1 ), simvastatin ( 2 ), dihydroartemisinin ( 3 ), tanshinone I ( 4 ), cryptotanshinone ( 5 ), gossypol ( 6 ) and dioscin ( 7 ) on PARP1 expression in melanoma A-375 cells. Although no statistical difference were found, a inhibition tendency on PARP1 expression for simvastatin and thanshinone I could be seen in the band.…”

Section: Figurementioning

confidence: 99%

“…Melanoma is a heterogeneous disease and one of the most aggressive forms of skin tumour with poor prognosis (7). Melanoma is associated with numerous genetic mutations or alterations in signalling pathways (e.g.…”

Section: Introductionmentioning

confidence: 99%

Tanshinone I and simvastatin inhibit melanoma tumour cell growth by regulating poly (ADP ribose) polymerase 1 expression

Zhang

Huang

et al. 2020

Mol Med Rep

View full text Add to dashboard Cite

“…Malignant melanoma is an aggressive malignant tumor derived from melanocytes, and its incidence is increasing worldwide [ 1 , 2 ]. Melanoma accounts for a small percentage of skin cancers, but accounts for the majority of deaths from such cancers [ 3 ]. Although melanoma can occur all over the body, it occurs most frequently on the skin.…”

Section: Introductionmentioning

confidence: 99%

Preoperative Screening CT and PET/CT Scanning for Acral Melanoma: Is it Necessary?

Ide

Ito

Wada-Ohno

et al. 2021

JCM

View full text Add to dashboard Cite

The efficacy of preoperative imaging for acral melanoma (AM) has not been fully evaluated. We examined the accuracy of imaging modalities in the detection of nodal and distant metastases in patients with AM. A retrospective review of 109 patients with AM was performed. All patients had no clinical signs suggestive of distant metastases, and underwent preoperative screening computed tomography (CT) and positron emission tomography (PET)/CT scans. Of 100 patients without lymphadenopathy, 17 patients were suspected of having nodal metastasis in CT and PET/CT, but only two of them were confirmed on histopathological analysis. On the other hand, 12 out of 83 negatively imaged patients showed histopathological signs of nodal metastasis; thus, the sensitivity and specificity of nodal detection were 14.3% and 82.6%, respectively. Regard to the detection of distant metastases, four patients were suspected of having metastasis, but this was later ruled out. The remaining 96 negatively imaged patients were confirmed to have no metastasis at the time of CT and PET/CT by the follow-up. In contrast, distant metastases were found by CT and PET/CT in four of nine patients (44.4%) with lymphadenopathy. Routine preoperative CT and PET/CT for AM patients without lymphadenopathy may not be warranted because of low sensitivity and specificity, but it can be considered for those with lymphadenopathy.

show abstract

Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma

Abstract: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma (Review)

Cited by 46 publications

References 403 publications

Staging 18F-FDG PET/CT influences the treatment plan in melanoma patients with satellite or in-transit metastases

Staging 18F-FDG PET/CT influences the treatment plan in melanoma patients with satellite or in-transit metastases

Tanshinone I and simvastatin inhibit melanoma tumour cell growth by regulating poly (ADP ribose) polymerase 1 expression

Preoperative Screening CT and PET/CT Scanning for Acral Melanoma: Is it Necessary?

Contact Info

Product

Resources

About

Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma

Abstract: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma (Review)

Cited by 46 publications

References 403 publications

Staging 18F-FDG PET/CT influences the treatment plan in melanoma patients with satellite or in-transit metastases

Staging 18F-FDG PET/CT influences the treatment plan in melanoma patients with satellite or in-transit metastases

Tanshinone&nbsp;I and simvastatin inhibit melanoma tumour cell growth by regulating poly (ADP ribose) polymerase&nbsp;1 expression

Preoperative Screening CT and PET/CT Scanning for Acral Melanoma: Is it Necessary?

Contact Info

Product

Resources

About

Tanshinone I and simvastatin inhibit melanoma tumour cell growth by regulating poly (ADP ribose) polymerase 1 expression